Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques

YIN Xiaoya; WANG Cheng; MING Guojun; HANG Taijun

doi:10.11665/j.issn.1000-5048.20170611

Journal of China Pharmaceutical University > 2017 > 48(6): 701-710. > DOI: 10.11665/j.issn.1000-5048.20170611

YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611

Citation:

PDF (1479 KB)

Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques

More Information

Graphical Abstract

Abstract

Abstract

To identify the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques, an Ultimate XB-C₁₈(250 mm×4. 6 mm, 5 μm)column was used for separation of the related substances with methanol and 0. 1% ammonium acetate buffer as the mobile phases in gradient elution. Electrospray positive ionization high resolution TOF/MS was used for the determination of the accurate mass and elemental composition of parent［M+H］⁺ ions of the related substances, and triple quadrupole tandem mass spectrometry was employed for the product mass spectra determination. Eleven major related substances were detected and identified to be one synthesis intermediate, six by-products and four degradation products, by using LC-MS determination, spectra elucidation, and further synthetic process and stress degradation mechanisms analysis. The results are useful for pioglitazone hydrochloride manufacturing processes optimization and quality control.
- pioglitazone hydrochloride,
- related substances,
- structural identification,
- LC-MS

FullText(HTML)

References (19)

References

[1]	Gillies PS,Dunn CJ.Pioglitazone[J].Drugs,2000,60(2):333-343.
[2]	Bajpeyi S, Pasarica M, Conley KE, et al. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function[J].Metab Clin Exp,2017,69:24-32.
[3]	Yasmin S,Jayaprakash V.Thiazolidinediones and PPAR orchestra as antidiabetic agents:from past to present[J].Eur J Med Chem,2017,126:879-893.
[4]	Berger JP,Akiyama TE,Meinke PT.PPARs:therapeutic targets for metabolic disease[J].Trends Pharmacol Sci,2005,26(5):244-251.
[5]	Smith U.Pioglitazone:mechanism of action[J].Int J Clin Pract Suppl,2001(121):13-18.
[6]	Derosa G.Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus:comparison with other oral antihyperglycaemic agents[J].Drugs,2010,70(15):1945-1961.
[7]	Qingju LI,Pengnuo LI,Tian C.Effects of treatment of pioglitazone combined with insulin on beta-cell function[J].J Med Forum,2005,26(1):32-34.
[8]	Stolar M.Safety and efficacy of pioglitazone/metformin combination therapy in treatment of type 2 diabetes:a rationale for earlier use[J].Clin Med Insights Ther,2009,1(3):445-451.
[9]	Sen S, Sinha S, Gupta K. Comparative evaluation of effects of combined oral anti-diabetic drugs(sulfonylurea plus pioglitazone and sulfonylurea plus metformin)over lipid parameters in type 2 diabetic patients[J].Int J Basic Clin Pharmacol,2013,2(3):257.
[10]	Srinivasulu D,Sastry BS,Prakash GO,et al.A new RP-HPLC method for separation and determination of process related impurities in pioglitazone hydrochloride API[J].J Sci Ind Res,2014,73(9):618-621.
[11]	Xun YB,Jiang LG,Kai D,et al.The related substances research and product evaluation for pioglitazone hydrochloride oral solid dosage form[J].Drug Stand China(中国药品标准),2011,12(6):450-454.
[12]	Rashmitha N, Rao CS, Chandra K, et al. A validated stability indicating HPLC method for the determination of impurities in pioglitazone hydrochloride[J].Der Pharma Chemica,2010,2(5):426-433.
[13]	Chinnalalaiah R, Pigili R, Avanapu SR. Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma[J].Ann Pharm Fr,2017,75(2):105-111.
[14]	Jagadeesh B,Bharathi D V,Pankaj C,et al.Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone,hydroxypioglitazone and metformin in human plasma by LC-MS/MS:application to a pharmacokinetic study[J].J Chromatog B,2013,930:136-145.
[15]	Karraa VK,Pillia NR,Inamadugub JK,et al.Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study[J].J Pharm Anal,2012,02(3):167-173.
[16]	Ramulu K,Kumar TT,Krishna SR,et al.Identification,isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance[J].Pharmazie,2010,65(3):162-168.
[17]	ICH.Stability testing of new drug substances and products[EB/OL].http://www.ich.org/products/guidelines/quality/quality-single/article/stability-testing-of-new-drug-substances-and-products.html.
[18]	Ngwa G.Forced degradation as an integral part of HPLC stability-indicating method development[J].Drug Deliv Technol,2010,10(5):56-59.
[19]	Rawat T,Pandey IP.Forced degradation studies for drug substances and drug products-scientific and regulatory considerations[J].J Pharm Sci Res,2015,7(5):238-241.

Cited By

Get Citation

PDF

XML

Article views (700) PDF downloads (1543)

Turn off MathJax

Article Contents

Abstract

References

Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques

Abstract

References

Catalog

Export File

Citation

Format

Content